HALO Halozyme Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: HALO

Price (delayed)

$56.23

Market cap

$7.16B

P/E Ratio

22.95

Dividend/share

N/A

EPS

$2.45

Enterprise value

$8.49B

Halozyme is a biopharmaceutical company focused on bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in ...

Highlights
The company's equity has surged by 170% YoY and by 112% QoQ
HALO's EPS has surged by 84% year-on-year and by 15% since the previous quarter
The stock's price to earnings (P/E) is 22% more than its last 4 quarters average of 18.7
Halozyme Therapeutics's quick ratio has decreased by 2.1% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.halozyme.com
Peers: MNKD LLY BAX PFE

Key stats

What are the main financial stats of HALO
Market
Shares outstanding
127.27M
Market cap
$7.16B
Enterprise value
$8.49B
Valuations
Price to earnings (P/E)
22.95
Price to book (P/B)
40.11
Price to sales (P/S)
8.27
EV/EBIT
20.67
EV/EBITDA
17.14
EV/Sales
9.84
Earnings
Revenue
$862.99M
EBIT
$410.85M
EBITDA
$495.45M
Free cash flow
$423.57M
Per share
EPS
$2.45
Free cash flow per share
$3.34
Book value per share
$1.4
Revenue per share
$6.8
TBVPS
$7.64
Balance sheet
Total assets
$1.84B
Total liabilities
$1.66B
Debt
$1.5B
Equity
$177.81M
Working capital
$741.95M
Liquidity
Debt to equity
8.44
Current ratio
6.64
Quick ratio
5.01
Net debt/EBITDA
2.7
Margins
EBITDA margin
57.4%
Gross margin
78.5%
Net margin
36.9%
Operating margin
44%
Efficiency
Return on assets
17.5%
Return on equity
192.7%
Return on invested capital
19.5%
Return on capital employed
24%
Return on sales
47.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HALO stock price

How has the Halozyme Therapeutics stock price performed over time
Intraday
0.46%
1 week
4.05%
1 month
8.13%
1 year
28.53%
YTD
52.14%
QTD
7.39%

Financial performance

How have Halozyme Therapeutics's revenue and profit performed over time
Revenue
$862.99M
Gross profit
$677.47M
Operating income
$379.31M
Net income
$318.8M
Gross margin
78.5%
Net margin
36.9%
HALO's net income has surged by 76% year-on-year and by 13% since the previous quarter
The company's operating income has surged by 54% YoY and by 12% QoQ
The net margin has grown by 43% YoY and by 9% from the previous quarter
The operating margin is up by 26% year-on-year and by 8% since the previous quarter

Growth

What is Halozyme Therapeutics's growth rate over time

Valuation

What is Halozyme Therapeutics stock price valuation
HALO P/E details
P/E
22.95
P/B
40.11
P/S
8.27
EV/EBIT
20.67
EV/EBITDA
17.14
EV/Sales
9.84
HALO's EPS has surged by 84% year-on-year and by 15% since the previous quarter
The stock's price to earnings (P/E) is 22% more than its last 4 quarters average of 18.7
The company's equity has surged by 170% YoY and by 112% QoQ
HALO's price to book (P/B) is 15% higher than its last 4 quarters average of 34.7 and 2.9% higher than its 5-year quarterly average of 38.8
The price to sales (P/S) is 35% higher than the last 4 quarters average of 6.1 but 33% lower than the 5-year quarterly average of 12.3
The company's revenue rose by 22% YoY and by 4.1% QoQ

Efficiency

How efficient is Halozyme Therapeutics business performance
Halozyme Therapeutics's return on assets has surged by 73% YoY and by 11% QoQ
The ROE has soared by 66% YoY but it has contracted by 6% from the previous quarter
HALO's return on invested capital has surged by 50% year-on-year and by 10% since the previous quarter
HALO's return on sales is up by 36% year-on-year and by 7% since the previous quarter

Dividends

What is HALO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HALO.

Financial health

How did Halozyme Therapeutics financials performed over time
The company's total assets is 11% higher than its total liabilities
The company's total assets rose by 8% YoY and by 6% QoQ
Halozyme Therapeutics's quick ratio has decreased by 2.1% YoY
The company's equity has surged by 170% YoY and by 112% QoQ
Halozyme Therapeutics's debt to equity has plunged by 63% YoY and by 53% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.